Showing results (11-20 of 94) with videos related to
Sort By:
Pageof 10
Innovations in Clinical Neuroscience|June 18, 2020
Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific MeetingMonica Javidnia, Mark Frasier, Ira Shoulson, et al.Therapeutic Innovation & Regulatory Science|September 21, 2018
Adaptive Design Applied to Identification of the Minimum Effective Dose in Schizophrenia: Simulations of Scientific and Commercial ValueTom Parke, Vladimir Dragalin, Ibrahim Turkoz, et al.Neuropsychiatric Disease and Treatment|February 3, 2009
Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophreniaIbrahim Turkoz, Cynthia A Bossie, Bryan Dirks, et al.International Clinical Psychopharmacology|January 27, 2010
Risperidone long-acting therapy in stable patients with recently diagnosed schizophreniaWayne Macfadden, Cynthia A Bossie, Ibrahim Turkoz, et al.Innovations in Clinical Neuroscience|May 26, 2016
The Direct and Indirect Effects of Paliperidone Extended-release on Depressive Symptoms in Schizoaffective Disorder: A Path AnalysisIbrahim Turkoz, Dong-Jing Fu, Cynthia A Bossie, et al.Neuropsychopharmacology Reports|September 11, 2024
Clinical effectiveness of paliperidone palmitate 3-monthly and 1-monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims databaseChih-Lin Chiang, Madoka Chinen, Mehmet Daskiran, et al.Neuropsychiatric Disease and Treatment|October 20, 2010
Role of paliperidone extended-release in treatment of schizoaffective disorderCarla M Canuso, Ibrahim Turkoz, Dong Jing Fu, et al.Journal of Affective Disorders|June 26, 2009
Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptomsCarla M Canuso, Ibrahim Turkoz, John J Sheehan, et al.Expert Opinion on Pharmacotherapy|November 17, 2017
Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safetyTianmei Si, Jianmin Zhuo, Ibrahim Turkoz, et al.Journal of Affective Disorders|January 24, 2016
Rapid onset of treatment effects on psychosis, depression, and mania in patients with acute exacerbation of schizoaffective disorder following treatment with oral extended-release paliperidoneDong-Jing Fu, Ibrahim Turkoz, Cynthia A Bossie, et al.Pageof 10